Is Samsung Bio (207940) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.2% / 30% | 2.0% / 30% | 0.9% / 30% | 1.01% / 5% | ✓ HALAL |
| DJIM | 1.2% / 33% | 2.0% / 33% | 0.9% / 33% | 1.01% / 5% | ✓ HALAL |
| MSCI | 8.4% / 33% | 13.4% / 33% | 5.9% / 33% | 1.01% / 5% | ✓ HALAL |
| S&P | 1.2% / 33% | 2.0% / 33% | 0.9% / 33% | 1.01% / 5% | ✓ HALAL |
| FTSE | 8.4% / 33% | 13.4% / 33% | 5.9% / 50% | 1.01% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 55.2% | |
| Operating Margin | 41.1% | |
| Net Margin | 39.2% | |
| Return on Equity (ROE) | 17.6% | |
| Return on Assets (ROA) | 9.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $2.2T |
| Free Cash Flow | $772.7B |
| Total Debt | $927.1B |
| Debt-to-Equity | 12.4 |
| Current Ratio | 1.7 |
| Total Assets | $11.1T |
Price & Trading
| Last Close | KRW 1,585,000.00 |
| 50-Day MA | KRW 1,698,520.00 |
| 200-Day MA | KRW 1,674,026.00 |
| Avg Volume | 58K |
| Beta | 0.2 |
|
52-Week Range
KRW 1,501,000.00
| |
About Samsung Bio (207940)
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance. In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Purification Calculator
As a halal stock with 1.01% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Samsung Bio (207940) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Samsung Bio is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Samsung Bio's debt ratio?
Samsung Bio's debt ratio is 1.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 8.4%.
Does Samsung Bio require dividend purification?
Yes, Samsung Bio has an impermissible income ratio of 1.01%, which means 1.01% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Samsung Bio's key financial metrics?
Samsung Bio has a market capitalization of $74.3T, and revenue of $4.6T. The company maintains a gross margin of 55.2% and a net margin of 39.2%. Return on equity stands at 17.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.